Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Hepatitis C virus recombinants are rare even among intravenous drug users
Journal of Medical Virology, Volume 82, No. 2, Year 2010
Notification
URL copied to clipboard!
Description
Systematic studies of the circulation of hepatitis C virus (HCV) recombinants in different parts of the world have been initiated only recently, and no detailed information on this subject is available. The aim of the current investigation was to determine the frequency of HCV recombinants in intravenousdrug users (IVDU) fromtwo European countries. HCV RNA from serum samples was tested by RT-PCR with primers derived from the core andNS5B regions with subsequent sequencing and genotype assignment. The 118 samples from Germany (100%) and 45 out of 47 (96%) sera from Russia demonstrated concordant genotyping results. In the two genotype discrepant sera from Russia 2k/1b recombinants were identified. In order to test the hypothesis that the individuals fromthe IVDUgroupmightbemultiplyexposedto various genotypes, 145 out of 165 genotyped serum samples, which were found to be positive for anti-NS4 antibodies, were serotyped with the Murex HCV serotyping kit that is based on detection of antibodies to type-specific peptides derived from the NS4 proteins of different HCV genotypes. Discrepancy in genotype and serotype attributionswas observed in 11% cases. Retesting of 99 type 1a or 3a samples with a set of type- and subtype-specific primers revealed the presence of a mixed infection only in one case (1a/3a). Thus, the cases of themixed infectionwith differentHCV genotypes as well as the recombinant forms of HCV are very rare even in such a highly exposed group as IVDU. © 2009Wiley-Liss, Inc.
Authors & Co-Authors
Viazov, Sergei O.
Germany, Essen
Universitätsklinikum Essen
Ross, Stefan S.
Germany, Essen
Universitätsklinikum Essen
Kyuregyan, Karen K.
Russian Federation, Moscow
Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences
Timm, Joerg
Germany, Essen
Universitätsklinikum Essen
Neumann-Haefelin, Christoph
Germany, Freiburg Im Breisgau
Universitätsklinikum Freiburg
Isaeva, Olga V.
Russian Federation, Moscow
Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences
Popova, Oksana E.
Russian Federation, Moscow
Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences
Dmitriev, Petr N.
Russian Federation, Moscow
Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences
Sharkawi, Fathia El
Egypt, Helwan
Helwan University
Thimme, Robert
Germany, Freiburg Im Breisgau
Universitätsklinikum Freiburg
Michailov, Michail I.
Russian Federation, Moscow
Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences
Roggendorf, Michael
Germany, Essen
Universitätsklinikum Essen
Statistics
Citations: 32
Authors: 12
Affiliations: 4
Identifiers
Doi:
10.1002/jmv.21631
ISSN:
01466615
e-ISSN:
10969071
Research Areas
Genetics And Genomics
Infectious Diseases